See more : Eden Innovations Ltd (EDE.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Cryoport, Inc. (CYRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cryoport, Inc., a leading company in the Integrated Freight & Logistics industry within the Industrials sector.
You may be interested
- VeriSign, Inc. (VRS.DE) Income Statement Analysis – Financial Results
- Bigbloc Construction Limited (BIGBLOC.NS) Income Statement Analysis – Financial Results
- Deutsche Pfandbriefbank AG (PBBGF) Income Statement Analysis – Financial Results
- Vanguard International Semiconductor Corporation (5347.TWO) Income Statement Analysis – Financial Results
- Mivne Real Estate (K.D) Ltd (MVNE.TA) Income Statement Analysis – Financial Results
Cryoport, Inc. (CYRX)
About Cryoport, Inc.
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 233.26M | 237.28M | 222.61M | 78.70M | 33.94M | 19.63M | 11.95M | 7.68M | 5.88M | 3.94M | 2.66M | 1.10M | 555.64K | 475.50K | 117.96K | 35.12K | 83.56K | 67.10K | 152.30K | 271.43K |
| Cost of Revenue | 133.92M | 133.40M | 126.03M | 42.36M | 16.59M | 9.39M | 5.99M | 4.58M | 3.99M | 2.77M | 2.22M | 1.59M | 1.39M | 1.30M | 717.71K | 546.15K | 386.37K | 176.94K | 315.65K | 499.65K |
| Gross Profit | 99.33M | 103.87M | 96.58M | 36.33M | 17.35M | 10.24M | 5.97M | 3.10M | 1.89M | 1.17M | 436.96K | -487.28K | -836.82K | -827.48K | -599.75K | -511.03K | -302.81K | -109.84K | -163.35K | -228.22K |
| Gross Profit Ratio | 42.59% | 43.78% | 43.38% | 46.17% | 51.12% | 52.18% | 49.91% | 40.39% | 32.14% | 29.70% | 16.43% | -44.28% | -150.61% | -174.02% | -508.46% | -1,454.93% | -362.37% | -163.68% | -107.26% | -84.08% |
| Research & Development | 18.04M | 15.72M | 16.84M | 9.48M | 3.74M | 1.84M | 1.21M | 598.11K | 550.26K | 352.58K | 409.11K | 425.45K | 491.85K | 449.13K | 284.85K | 297.38K | 166.23K | 87.86K | 254.49K | 98.70K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 17.47M | 9.80M | 7.42M | 6.45M | 5.93M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 13.82M | 7.25M | 5.23M | 4.82M | 4.16M | 2.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 146.88M | 120.06M | 97.56M | 56.86M | 31.29M | 17.04M | 12.65M | 11.27M | 10.08M | 6.41M | 5.11M | 5.41M | 6.11M | 4.32M | 3.31M | 2.39M | 2.55M | 1.90M | 1.02M | 622.80K |
| Other Expenses | 49.57M | -5.52M | -2.82M | -929.00K | 772.07K | 77.63K | 14.34K | -6.77K | -9.90K | -4.27K | -13.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -630.00 | -3.00 | 0.00 |
| Operating Expenses | 214.49M | 135.78M | 114.41M | 66.34M | 35.03M | 18.88M | 13.86M | 11.87M | 10.63M | 6.76M | 5.52M | 5.84M | 6.60M | 4.77M | 3.60M | 2.68M | 2.72M | 1.99M | 1.28M | 721.50K |
| Cost & Expenses | 348.41M | 269.18M | 240.44M | 108.71M | 51.62M | 28.27M | 19.85M | 16.44M | 14.62M | 9.53M | 7.74M | 7.42M | 7.99M | 6.07M | 4.32M | 3.23M | 3.10M | 2.16M | 1.59M | 1.22M |
| Interest Income | 0.00 | 8.47M | 3.25M | 761.00K | 784.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.94K | 15.57K | 8.16K | 32.10K | 50.08K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 5.50M | 6.14M | 4.69M | 2.56M | 1.37M | 69.25K | 15.69K | 139.42K | 1.07M | 1.43M | 784.45K | 72.86K | 527.75K | 618.77K | 7.03M | 2.69M | 1.59M | 228.37K | 80.38K | 85.77K |
| Depreciation & Amortization | 27.49M | 22.77M | 20.25M | 9.87M | 2.42M | 857.94K | 664.83K | 374.20K | 239.23K | 197.94K | 311.59K | 393.96K | 343.03K | 245.48K | 150.09K | 81.98K | 1.34M | 111.22K | 88.75K | 92.60K |
| EBITDA | -66.36M | -6.19M | -248.91M | -20.31M | -14.49M | -8.61M | -7.21M | -13.38M | -8.51M | -5.40M | -18.47M | -5.91M | -6.96M | -5.29M | 1.53M | -13.93M | -2.93M | -1.99M | -1.35M | -857.12K |
| EBITDA Ratio | -28.45% | -15.77% | -9.28% | -39.31% | -49.80% | -43.65% | -65.90% | -109.37% | -148.77% | -142.23% | -706.79% | -538.87% | -1,274.16% | -1,122.18% | -3,424.14% | -8,773.52% | -2,005.44% | -2,958.25% | -887.85% | -315.11% |
| Operating Income | -115.16M | -31.90M | -17.83M | -30.01M | -17.68M | -8.64M | -7.89M | -8.77M | -8.74M | -5.59M | -5.08M | -6.32M | -7.43M | -5.60M | -4.20M | -3.20M | -3.02M | -2.10M | -1.44M | -949.72K |
| Operating Income Ratio | -49.37% | -13.45% | -8.01% | -38.13% | -52.07% | -44.05% | -66.02% | -114.16% | -148.60% | -142.12% | -190.92% | -574.67% | -1,338.05% | -1,177.08% | -3,558.31% | -9,098.32% | -3,613.77% | -3,123.99% | -946.12% | -349.89% |
| Total Other Income/Expenses | 15.81M | -3.19M | -256.01M | -2.73M | -594.90K | -891.03K | -1.36K | -4.34M | -1.08M | -1.43M | -14.49M | -56.38K | -396.65K | -553.60K | -1.45M | -13.51M | -1.54M | -228.37K | -80.38K | -87.59K |
| Income Before Tax | -99.35M | -35.09M | -273.84M | -32.74M | -18.27M | -9.54M | -7.89M | -13.11M | -9.82M | -7.03M | -19.56M | -6.38M | -7.83M | -6.15M | -5.65M | -16.70M | -4.56M | -2.32M | -1.52M | -1.04M |
| Income Before Tax Ratio | -42.59% | -14.79% | -123.02% | -41.60% | -53.83% | -48.59% | -66.03% | -170.70% | -166.89% | -178.52% | -735.50% | -579.79% | -1,409.43% | -1,293.51% | -4,789.89% | -47,555.95% | -5,459.83% | -3,464.31% | -998.90% | -382.17% |
| Income Tax Expense | 239.00K | 2.24M | 1.69M | -45.00K | 61.58K | 19.95K | 5.14K | 5.67K | 3.63K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 1.60K | 800.00 | 800.00 |
| Net Income | -99.59M | -37.33M | -275.53M | -32.69M | -18.33M | -9.56M | -7.90M | -13.11M | -9.82M | -7.03M | -19.57M | -6.38M | -7.83M | -6.15M | -5.65M | -16.71M | -4.56M | -2.33M | -1.52M | -1.04M |
| Net Income Ratio | -42.69% | -15.73% | -123.77% | -41.54% | -54.01% | -48.69% | -66.08% | -170.77% | -166.95% | -178.56% | -735.56% | -579.94% | -1,409.72% | -1,293.84% | -4,791.25% | -47,560.50% | -5,461.75% | -3,466.70% | -999.42% | -382.46% |
| EPS | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| EPS Diluted | -2.21 | -0.76 | -6.00 | -0.85 | -0.55 | -0.34 | -0.34 | -0.92 | -1.34 | -1.31 | -4.48 | -1.89 | -3.03 | -5.18 | -12.63 | -45.35 | -12.96 | -8.42 | -5.70 | -6.49 |
| Weighted Avg Shares Out | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.20M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
| Weighted Avg Shares Out (Dil) | 48.74M | 48.99M | 45.93M | 38.58M | 33.39M | 28.21M | 22.96M | 14.22M | 7.34M | 5.37M | 4.37M | 3.37M | 2.59M | 1.19M | 447.59K | 368.34K | 352.15K | 276.39K | 266.97K | 159.95K |
CryoPort (CYRX) Moves 26.7% Higher: Will This Strength Last?
CryoPort (CYRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
As The Schall Law Firm Starts An Investigation Into Allegations, Shareholders Of Cryoport Inc Are Encouraged To Contact
LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Shareholders Of Cryoport Inc Are Urged To Reach Out As The Schall Law Firm Begins A Probe Into Claims
LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Cryoport Inc Shareholders Are Encouraged To Contact As The Schall Law Firm Initiates An Investigation Into Allegations
LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
CryoPort (CYRX) Loses -43.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for CryoPort (CYRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is...
The Schall Law Firm Begins Investigation Into Claims Against Cryoport Inc And Encourages Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Cryoport Inc Is Under Investigation By The Schall Law Firm And Shareholders Are Encouraged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
The Schall Law Firm Initiates Investigation Into Cryoport Inc And Calls On Its Shareholders To Connect
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
As The Schall Law Firm Begins Investigating Claims Against Cryoport Inc, It Encourages Its Shareholders To Contact
LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
As The Schall Law Firm Starts Probing Allegations Against Cryoport Inc, Its Shareholders Are Urged To Get In Touch
LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cryoport, Inc. ("Cryoport" or "the Company") (NASDAQ:CYRX) for violations...
Source: https://incomestatements.info
Category: Stock Reports